Summary of Collegium Pharmaceutical Conference Call Company Overview - **Company**: Collegium Pharmaceutical (NasdaqGS:COLL) - **Focus**: Chronic pain management and ADHD with five marketed products - **Revenue**: Expected to reach $780 million in 2025, representing a 24% year-over-year growth [1][3][11] Core Business Insights - **Flagship Products**: - Xtampza: Extended-release oxycodone with abuse-deterrent technology - Belbuca: Long-acting opioid using buprenorphine buccal film technology - Nucynta: Treats severe and persistent pain, including diabetic neuropathy - Jornay PM: Unique evening-dosed ADHD medication [2][3][11] - **Recent Acquisition**: IronSure in 2024, adding Jornay PM to the portfolio [2] Financial Performance - **Q3 2025 Results**: - Revenues: $209.4 million, up 31% year-over-year - Adjusted EBITDA: $133 million, up 27% year-over-year - Cash from operations: Nearly $80 million, total cash balance of $286 million [6][11] - **Debt Management**: - Net debt to adjusted EBITDA ratio down to 1.2 times, expected to be below 1 by year-end [7][12] Growth Strategy - **Three Core Pillars**: 1. Grow Jornay through strategic investments in sales and marketing 2. Maximize the value of the pain portfolio 3. Strategically deploy capital for business development, debt repayment, and share repurchases [4][12] - **Market Position**: - Jornay PM is the fastest-growing stimulant for ADHD, with a 20% growth in prescriptions [8][9] - Pain portfolio revenue growth: 10% for Belbuca and 2% for Xtampza in Q3 [11] Market Dynamics - **ADHD Market**: - Approximately 100 million prescriptions annually, with 90% being stimulant medications - Jornay PM has a unique evening dosing, leading to high differentiation and prescriber intent [7][8] - **Pain Management Market**: - Collegium's pain portfolio represents about half of the branded extended-release market - Minimal regulatory or clinical risks compared to peers [11][12] Shareholder Value - **Share Repurchases**: Over $220 million repurchased since 2021, with an authorization for an additional $150 million through 2026 [1][12] - **Future Outlook**: Confident in the strength and durability of the business, with robust revenue growth and strong cash flow generation expected [11][13]